Disclosure : The University of Bergen/Haukeland University Hospital/Dana Farber Cancer Institute/Harvard through BTO (Bergen Teknologioverføring AS): Some aspects relating to prognostic marker for endometrial cancer is subject on pending intellectual property rights (US 12/962,946) and some aspects are covered by license agreements.
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
Powered by MULTIWEBCAST Technologies. MULTIWEBCAST PLATFORM Version 4.1000. All rights reserved.